{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:40:20Z","timestamp":1787726420274,"version":"build-2784847793"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A considerable proportion of metastatic melanoma (mM) patients do not respond to immune checkpoint inhibitors (ICIs). There is a great need to develop noninvasive biomarkers to detect patients, who do not respond to ICIs early during the course of treatment. The aim of this study was to evaluate the role of early [\n                      <jats:sup>18<\/jats:sup>\n                      F]2fluoro-2-deoxy-D-glucose PET\/CT (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT) at week four (W4) and other possible prognostic biomarkers of survival in mM patients receiving ICIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      . In this prospective noninterventional clinical study, mM patients receiving ICIs regularly underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT: at baseline, at W4 after ICI initiation, at week sixteen and every 16 weeks thereafter. The tumor response to ICIs at W4 was assessed via modified European Organisation for Research and Treatment of Cancer (EORTC) criteria. Patients with progressive metabolic disease (PMD) were classified into the no clinical benefit group (no-CB), and those with other response types were classified into the clinical benefit group (CB). The primary end point was survival analysis on the basis of the W4\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT response. The secondary endpoints were survival analysis on the basis of LDH, the number of metastatic localizations, and immune-related adverse events (irAEs). Kaplan-Meier analysis and univariate Cox regression analysis were used to assess the impact on survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 71 patients were included. The median follow-up was 37.1 months (952% CI = 30.1\u201338.0). Three (4%) patients had only baseline scans due to rapid disease progression and death prior to W4\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET\/CT. Fifty-one (72%) patients were classified into the CB group, and 17 (24%) were classified into the no-CB group. There was a statistically significant difference in median overall survival (OS) between the CB group (median OS not reached [NR]; 95% CI = 17.8 months \u2013 NR) and the no-CB group (median OS 6.2 months; 95% CI = 4.6 months \u2013 NR; p = 0.003). Univariate Cox analysis showed HR of 0.4 (95% CI = 0.18 \u2013 0.72; p = 0.004). median OS was also significantly longer in the group with normal serum LDH levels and the group with irAEs and cutaneous irAEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Evaluation of mM patients with early\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET\/CT at W4, who were treated with ICIs, could serve as prognostic imaging biomarkers. Other recognized prognostic biomarkers were the serum LDH level and occurrence of cutaneous irAEs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0014","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T13:35:52Z","timestamp":1740663352000},"page":"43-53","source":"Crossref","is-referenced-by-count":4,"title":["Early-time-point\n                    <sup>18<\/sup>\n                    F-FDG-PET\/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy"],"prefix":"10.2478","volume":"59","author":[{"given":"Nezka","family":"Hribernik","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Strasek","sequence":"additional","affiliation":[{"name":"Faculty of Mathematics and Physics, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Studen","sequence":"additional","affiliation":[{"name":"Faculty of Mathematics and Physics, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Experimental Particle Physics Department, Jozef Stefan Institute , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Zevnik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Skalic","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jeraj","sequence":"additional","affiliation":[{"name":"Faculty of Mathematics and Physics, University of Ljubljana , Ljubljana , Slovenia"},{"name":"University of Wisconsin Carbone Cancer Centre , Madison , WI , USA"},{"name":"Department of Medical Physics, University of Wisconsin-Madison , Madison , WI , USA"},{"name":"Experimental Particle Physics Department, Jozef Stefan Institute , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rebersek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2026071215424929820_j_raon-2025-0014_ref_001","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al; CheckMate 067 Investigators. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2024; 392: 11-22. doi: 10.1056\/NEJMoa2407417","DOI":"10.1056\/NEJMoa2407417"},{"key":"2026071215424929820_j_raon-2025-0014_ref_002","doi-asserted-by":"crossref","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 2024; 35: 1191-9. doi: 10.1016\/j.annonc.2024.08.2330","DOI":"10.1016\/j.annonc.2024.08.2330"},{"key":"2026071215424929820_j_raon-2025-0014_ref_003","doi-asserted-by":"crossref","unstructured":"Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, et al. Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma. J Clin Oncol 2022; 40: 1068-80. doi: 10.1200\/JCO.21.01701","DOI":"10.1200\/JCO.21.01701"},{"key":"2026071215424929820_j_raon-2025-0014_ref_004","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Livingstone E, Zimmer L. Treatment in metastatic mela-noma-time to rethink. Ann Oncol 2019; 30: 501-3. doi: 10.1093\/annonc\/mdz050","DOI":"10.1093\/annonc\/mdz050"},{"key":"2026071215424929820_j_raon-2025-0014_ref_005","doi-asserted-by":"crossref","unstructured":"Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab-real-world experience. Radiol Oncol 2020; 54: 119-27. doi: 10.2478\/raon-2020-0003.","DOI":"10.2478\/raon-2020-0003"},{"key":"2026071215424929820_j_raon-2025-0014_ref_006","doi-asserted-by":"crossref","unstructured":"Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, et al. Multiorgan immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol 2024; 25: 1053-69. doi: 10.1016\/S1470-2045(24)00278-X","DOI":"10.1016\/S1470-2045(24)00278-X"},{"key":"2026071215424929820_j_raon-2025-0014_ref_007","doi-asserted-by":"crossref","unstructured":"Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F] FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323-41. doi: 10.1007\/s00259-022-05780-2","DOI":"10.1007\/s00259-022-05780-2"},{"key":"2026071215424929820_j_raon-2025-0014_ref_008","doi-asserted-by":"crossref","unstructured":"Dimitriou F, Lo SN, Tan AC, Emmett L, Kapoor R, Carlino MS, et al. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 2022; 33: 99-106. doi: 10.1016\/j.annonc.2021.10.003","DOI":"10.1016\/j.annonc.2021.10.003"},{"key":"2026071215424929820_j_raon-2025-0014_ref_009","doi-asserted-by":"crossref","unstructured":"Santo G, Cuc\u00e8 M, Restuccia A, Del Giudice T, Tassone P, Cicone F, et al. Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications. Cancer Imaging 2024; 24: 125. doi: 10.1186\/s40644-024-00774-9","DOI":"10.1186\/s40644-024-00774-9"},{"key":"2026071215424929820_j_raon-2025-0014_ref_010","doi-asserted-by":"crossref","unstructured":"Hribernik N, Strasek K, Huff DT, Studen A, Zevnik K, Skalic K, et al. Role of quantitative imaging biomarkers in an early FDG-PET\/CT for detection of immune-related adverse events in melanoma patients: a prospective study. Radiol Oncol 2024; 58: 335-47. doi: 10.2478\/raon-2024-0045","DOI":"10.2478\/raon-2024-0045"},{"key":"2026071215424929820_j_raon-2025-0014_ref_011","doi-asserted-by":"crossref","unstructured":"Hribernik N, Huff DT, Studen A, Zevnik K, Klane\u010dek \u017d, Emamekhoo H, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging 2022; 49: 1857-69. doi: 10.1007\/s00259-021-05650-3","DOI":"10.1007\/s00259-021-05650-3"},{"key":"2026071215424929820_j_raon-2025-0014_ref_012","doi-asserted-by":"crossref","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med 2017; 58: 1421-8. doi: 10.2967\/jnumed.116.188839","DOI":"10.2967\/jnumed.116.188839"},{"key":"2026071215424929820_j_raon-2025-0014_ref_013","unstructured":"National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.2021. [cited 2023 Oct 23]. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf"},{"key":"2026071215424929820_j_raon-2025-0014_ref_014","doi-asserted-by":"crossref","unstructured":"Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, et al. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 2011; 12: 71. doi: 10.1186\/1471-2105-12-71","DOI":"10.1186\/1471-2105-12-71"},{"key":"2026071215424929820_j_raon-2025-0014_ref_015","doi-asserted-by":"crossref","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. doi: 10.1016\/s0959-8049(99)00229-4","DOI":"10.1016\/S0959-8049(99)00229-4"},{"key":"2026071215424929820_j_raon-2025-0014_ref_016","doi-asserted-by":"crossref","unstructured":"Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, et al. FDG PET\/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Clin Cancer Res 2024; 30: 1758-67. doi: 10.1158\/1078-0432.CCR-23-2390","DOI":"10.1158\/1078-0432.CCR-23-2390"},{"key":"2026071215424929820_j_raon-2025-0014_ref_017","doi-asserted-by":"crossref","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022; 28: 1178-88. doi: 10.1038\/s41591-022-01851-x","DOI":"10.1038\/s41591-022-01851-x"},{"key":"2026071215424929820_j_raon-2025-0014_ref_018","doi-asserted-by":"crossref","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 2024; 391: 1696-708. doi: 10.1056\/NEJMoa2402604","DOI":"10.1056\/NEJMoa2402604"},{"key":"2026071215424929820_j_raon-2025-0014_ref_019","doi-asserted-by":"crossref","unstructured":"Taghanaki SA, Zheng Y, Kevin Zhou S, Georgescu B, Sharma P, Xu D, et al. Combo loss: handling input and output imbalance in multiorgan segmentation. Comput Med Imaging Graph 2019; 75: 24-33. doi: 10.1016\/j.comp-medimag.2019.04.005","DOI":"10.1016\/j.compmedimag.2019.04.005"},{"key":"2026071215424929820_j_raon-2025-0014_ref_020","doi-asserted-by":"crossref","unstructured":"Huff DT, Ferjancic P, Nam\u00edas M, Emamekhoo H, Perlman SB, Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis. Biomed Phys Eng Express 2021; 7: 065019. doi: 10.1088\/2057-1976\/ac27c3","DOI":"10.1088\/2057-1976\/ac27c3"},{"key":"2026071215424929820_j_raon-2025-0014_ref_021","doi-asserted-by":"crossref","unstructured":"Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer 2024; 5: 557-71. doi: 10.1038\/s43018-024-00730-3","DOI":"10.1038\/s43018-024-00730-3"},{"key":"2026071215424929820_j_raon-2025-0014_ref_022","doi-asserted-by":"crossref","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol 2023; 7: 41. doi: 10.1038\/s41698-023-00380-1","DOI":"10.1038\/s41698-023-00380-1"},{"key":"2026071215424929820_j_raon-2025-0014_ref_023","doi-asserted-by":"crossref","unstructured":"Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 2020; 20: 36. doi: 10.1186\/s40644-020-00313-2","DOI":"10.1186\/s40644-020-00313-2"},{"key":"2026071215424929820_j_raon-2025-0014_ref_024","doi-asserted-by":"crossref","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021; 48: 428-48. doi: 10.1007\/s00259-020-04967-9","DOI":"10.1007\/s00259-020-04967-9"},{"key":"2026071215424929820_j_raon-2025-0014_ref_025","doi-asserted-by":"crossref","unstructured":"Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, et al. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET\/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST. Jpn J Radiol 2022; 40: 75-85. doi: 10.1007\/s11604-021-01174-w","DOI":"10.1007\/s11604-021-01174-w"},{"key":"2026071215424929820_j_raon-2025-0014_ref_026","doi-asserted-by":"crossref","unstructured":"Iravani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacologic intervention, Part 1: The role of 18F-FDG PET\/CT. J Nucl Med 2020; 61: 943-50. doi: 10.2967\/jnumed.119.234278","DOI":"10.2967\/jnumed.119.234278"},{"key":"2026071215424929820_j_raon-2025-0014_ref_027","doi-asserted-by":"crossref","unstructured":"Shreve JT, Khanani SA, Haddad TC. Artificial intelligence in oncology: current capabilities, future opportunities, and ethical considerations. Am Soc Clin Oncol Educ Book 2022; 42: 1-10. doi: 10.1200\/EDBK_350652","DOI":"10.1200\/EDBK_350652"},{"key":"2026071215424929820_j_raon-2025-0014_ref_028","doi-asserted-by":"crossref","unstructured":"de Groot DJA, Lub-de Hooge MN, van Meerten T, Brouwers AH, de Vries EGE. Facts and hopes for PET imaging-derived immunotherapy biomarkers. Clin Cancer Res 2024; 30: 5252-9. doi: 10.1158\/1078-0432.CCR-24-1427","DOI":"10.1158\/1078-0432.CCR-24-1427"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:23:29Z","timestamp":1783905809000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["10.2478\/raon-2025-0014"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0014","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}